YAP1 and gastric cancer: Although it is likely that miR-375 also suppresses other potential important targets such as the Hippo pathway through direct targeting YAP1, TEAD4 and CTGF (26), JAK2 (27), and PDK1 or 14-3-3zeta (28), the mechanisms of reduced GRIK1-AS1, as well as the downstream of IFIT2 in gastric cancer merit further investigation.